Automotive & Transportation
NBIX, CRNT, MOH, MRX, MCRL, CPTS Are Seasonally Ripe To Go Up In the Next Five Weeks
August 9, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), CERAGON NETWORKS LTD (NASDAQ:CRNT), MOLINA HEALTHCARE INC (NYSE:MOH), MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX), MICREL INC (NASDAQ:MCRL), CONCEPTUS INC (NASDAQ:CPTS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php
The following stocks are expected to go Up:
Symbol Company Expected Return Odds By The Following Date
NBIX NEUROCRINE BIOSCIENCES INC 9.25% 73.33% (11 of 15) Wednesday, September 21st 2011
CRNT CERAGON NETWORKS LTD 10.83% 72.73% (8 of 11) Tuesday, August 30th 2011
MOH MOLINA HEALTHCARE INC 8.57% 100.00% (8 of 8) Monday, September 12th 2011
MRX MEDICIS PHARMACEUTICAL-CL A 9.09% 68.42% (13 of 19) Wednesday, August 31st 2011
MCRL MICREL INC 8.19% 75.00% (12 of 16) Thursday, August 25th 2011
CPTS CONCEPTUS INC 7.17% 80.00% (12 of 15) Wednesday, August 24th 2011
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders. Its products in clinical development include Elagolix, a phase II product for endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for cardiovascular diseases; CRF1 Antagonist, a phase I product for treating mood disorders and irritable bowel syndrome; Vesicular Monoamine Transporter 2 Inhibitor, a phase I product for movement disorders and schizophrenia; and Elagolix, a phase I product for uterine fibroids, and mens and womens health. The companys research programs comprise Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic Drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. Its product pipeline also includes Indiplon 5mg and 10mg capsules, the FDA deemed approvable products, for the treatment of insomnia. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott Laboratories to develop and commercialize elagolix for the treatment of endometriosis-related pain; and Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
CERAGON NETWORKS LTD (NASDAQ:CRNT) - Ceragon Networks Ltd. offers wireless backhaul solutions that enable cellular operators and other wireless service providers to deliver voice and data services, such as Internet browsing, music, and video applications. The company offers its products under the brand name of FibeAir, which include IP-10/IP-MAX2-G, a high-capacity Ethernet that is used in wireless backhaul, worldwide interoperability for microwave access (WiMAX) backhaul, metro area networks, private networks, and long distance networks; IP-10/IP-MAX2, a high-capacity multi-service, which is used in wireless backhaul and private networks; and 640P, a high-capacity PDH multi-service used in wireless backhaul and business access. It also provides 2000/4800, an unlicensed multi-service that is used in private networks and business access; 1500P/1500R, a high-capacity synchronous digital hierarchy/synchronous optical networking, which is used in wireless backhaul and metro area networks; and 3200T, a high-capacity circuit-switched time-division multiplexer used in wireless backhaul and long distance networks. In addition, Ceragon offers turnkey project services that include advanced network and radio planning, site survey, solutions development, installation, maintenance, and training. The company serves WiMax carriers, Wireless Internet service providers, local exchange carriers, businesses, public institutions, and wireless service providers. It sells its products through various channels, including direct sales, original equipment manufacturers, resellers, distributors, and system integrators primarily in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company was formerly known as Giganet Ltd. and changed its name to Ceragon Networks Ltd. in September 2000. Ceragon Networks Ltd. was founded in 1996 and is headquartered in Tel Aviv, Israel.
MOLINA HEALTHCARE INC (NYSE:MOH) - Molina Healthcare, Inc., through its subsidiaries, operates as a multi-state managed care organization. It delivers health care services to persons eligible for Medicaid, Medicare, and other government-sponsored programs for low-income families and individuals through a network of primary care clinics. The company also contracts with primary care physicians, specialist physicians, physician groups, hospitals, and other medical care providers. As of December 31, 2009, it operated 17 company-owned primary care clinics in California. Molina Healthcare, Inc. provides licensed health plans in the states of California, Florida, Michigan, Missouri, New Mexico, Ohio, Texas, Utah, and Washington. The company was formerly known as American Family Care, Inc. and changed its name to Molina Healthcare, Inc. in 2000. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.
MEDICIS PHARMACEUTICAL-CL A (NYSE:MRX) - Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe. The companys products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis. Its primary products include DYSPORT for temporary improvement in the appearance of glabellar lines in adults younger than 65 years of age; LIPOSONIX to destroy targeted fat just beneath the skin in the treatment of the anterior abdomen; PERLANE and RESTYLANE for the correction of facial wrinkles and folds, such as nasolabial folds; SOLODYN for the treatment of inflammatory lesions of non-nodular acne vulgaris in patients 12 years of age and older; TRIAZ for the topical treatment of acne vulgaris; VANOS, a topical corticosteroid for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older; and ZIANA, a topical treatment of acne vulgaris in patients 12 years of age and older. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has strategic collaborations with Glenmark; Revance Therapeutics, Inc.; Hyperion Therapeutics, Inc.; Perrigo Israel Pharmaceuticals Ltd.; and IMPAX Laboratories, Inc. The company was founded in 1987 and is headquartered in Scottsdale, Arizona.
MICREL INC (NASDAQ:MCRL) - Micrel Incorporated, doing business as Micrel Semiconductor, designs, develops, manufactures, and markets high-performance analog power, mixed-signal, and digital integrated circuits (ICs) primarily in North America, Europe, and Asia. It offers power management products, including cloud, single-board, and enterprise servers; network switches and routers; storage area networks; and wireless base stations for the networking and communications infrastructure markets. The company also provides power management products for industrial, consumer, defense, and automotive electronics markets. In addition, it manufactures custom analog and mixed-signal circuits; and provides wafer foundry services for the customers who produce electronic systems for communications, consumer, and military applications. Further, the company offers radio frequency data communications products, including QwikRadio family of RF receivers and transmitters, which include garage door openers, lighting and fan controls, automotive keyless entry, and remote controls; and RadioWire transceivers for applications, such as remote metering, security systems, and factory automation. Additionally, it provides Ethernet products, which comprise physical layer transceivers, media access controllers, switches, and system-on-chip devices for the digital home and industrial/embedded networking markets. The companys products address a range of end markets, including cellular handsets, portable computing, enterprise and home networking, wide area and metropolitan area networks, digital televisions, and industrial equipment. Micrel Incorporated sells its products through a network of independent sales representatives, independent distributors, and stocking representative firms, as well as through a direct sales staff. The company was founded in 1978 and is based in San Jose, California.
CONCEPTUS INC (NASDAQ:CPTS) - Conceptus, Inc. designs, develops, and markets minimally invasive devices for reproductive medical applications. It offers Essure, a permanent birth control system for women. The Essure system delivers a micro-insert into a woman's fallopian tubes, causing benign tissue in-growth that blocks the fallopian tubes. The company distributes its products through direct sales force and distributor networks primarily to physicians and hospitals. It primarily operates in the United States, France, and the rest of Europe. Conceptus, Inc. was founded in 1992 and is headquartered in Mountain View, California.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641